Skip to main content

Table 1 Baseline participants’ demographics by disease activity stratification, as measured by RAPID3 (N = 249)

From: Barriers to treatment optimization and achievement of patients’ goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry

Mean (SD) unless otherwise specified

All survey participants (N = 249)

High disease activity (n = 175)

Moderate/low disease activity or near REM (n = 74)

p valuea

Age, years

51.7 (11.0)

50.9 (10.6)

53.7 (11.5)

0.06

Females, n (%)

229 (92.0)

163 (93.1)

66 (89.2)

0.29

Ethnicity, white, n (%)

225 (90.4)

154 (88.0)

71 (96.0)

0.05

Time since diagnosis, years (SD)

11.0 (9.5)

10.8 (9.3)

11.5 (10.1)

0.62

Some college education or above, n (%)

215 (86.4)

150 (85.7)

65 (87.8)

0.66

Full-time employment, n (%)

83 (33.3)

58 (33.1)

25 (33.8)

0.92

Private insurance, n (%)

154 (61.9)

112 (64.0)

42 (56.8)

0.28

Current RA therapy, n (%)

 Non-biologic DMARDs only

72 (28.9)

54 (30.9)

18 (24.3)

0.30

 Biologic DMARDs

150 (60.2)

106 (60.6)

44 (59.5)

0.87

 Steroid/NSAID/other/no treatmentb

27 (10.8)

15 (8.6)

12 (16.2)

0.08

Patient-reported outcomes, median (IQR)

 RAPID3 (0–30 scale)

15.0 (12.0–19.0)

18.0 (15.0–20.0)

8.0 (6.0–11.0)

< 0.0001

 PROMIS-CAT measures (0–100 scale)

  Pain interference

63.3 (60.3–66.9)

65.5 (62.7–67.8)

58.0 (55.8–61.5)

< 0.0001

  Fatigue

63.0 (58.7–67.9)

65.7 (62.3–69.4)

56.7 (50.8–62.3)

< 0.0001

  Physical function

37.8 (34.0–40.8)

35.5 (32.5–38.6)

43.2 (39.5–45.8)

< 0.0001

  Sleep disturbance

59.2 (54.3–63.0)

60.8 (55.8–64.9)

55.6 (50.4–61.8)

< 0.0001

  1. Participants with near REM: RAPID3 scores 1–3; low disease activity: RAPID3 scores 4–6; moderate disease activity: RAPID3 scores 7–12; high disease activity: RAPID3 scores 13–30. DMARD disease-modifying antirheumatic drug, IQR interquartile range, NSAID non-steroidal anti-inflammatory drug, PROMIS-CAT Patient-Reported Outcomes Measurement Information System – Computerized Adaptive Test, RA rheumatoid arthritis, RAPID3 Routine Assessment of Patient Index Data 3, REM remission, SD standard deviation
  2. aStatistical significance between moderate/low and high disease activity patient groups, p < 0.05; t tests were performed for continuous variables and chi square tests for categorical variables; p values are nominal in nature and should be interpreted in an exploratory manner
  3. bParticipants received prior DMARD treatment before baseline. PROMIS-CAT cut-offs for normal (score ≤ 55), low (score > 55–60), and medium (score > 60–70), and high pain interference, fatigue, and sleep disturbance (score > 70); PROMIS-CAT cut-offs for normal (score ≥ 45), low (score 40 < 45), medium (30 < 40), and high physical function (score < 30). Possible PROMIS-CAT scores ranged from 0 to 100